The EBI2-oxysterol axis promotes the development of intestinal lymphoid structures and colitis
Annika Wyss(University of Zurich), Benjamin Misselwitz(University of Zurich), Florian Ruiz(University Hospital of Geneva), Silvia Lang(University of Zurich), Martin Hersberger(University Children's Hospital Zurich), Tina Raselli(University of Zurich), Isabelle Frey‐Wagner(University of Zurich), René Roth(University of Zurich), Anja Moncsek(University Hospital of Zurich), Glynis Klinke(University of Zurich), Andreas W. Sailer(Novartis (Switzerland)), Michael Scharl(Swiss Integrative Center for Human Health), Marianne R. Spalinger(University of Zurich), Gérard Schmelczer(University of Zurich), Larissa Hering(University of Zurich), Kirstin Atrott(University of Zurich), Caroline Pot(University Hospital of Lausanne), Nathan Perkins(University of Zurich), Joachim C. Mertens(GastroZentrum Hirslanden Zürich), Gerhard Rogler(University Hospital of Zurich), Oliver Pabst(RWTH Aachen University)
Cited by 49
Related Papers
Cholangiocarcinoma 2020: the next horizon in mechanisms and management
|Nature Reviews Gastroenterology & Hepatology|2020|2.5k
Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA)
|Nature Reviews Gastroenterology & Hepatology|2016|1.4k
NASH limits anti-tumour surveillance in immunotherapy-treated HCC
|Nature|2021|1.3k
Extraintestinal Manifestations of Inflammatory Bowel Disease
|Inflammatory Bowel Diseases|2015|891